Indianapolis, Indiana — According to state and local development sources, POINT Biopharma Global plans to invest $2,225,928.00 to build out 3,325 square feet of new space in Indianapolis. The company plans to occupy the new space at 4850 W 78th St in Indianapolis, on or about December 1, 2023. According to the company website POINT Biopharma is a precision oncology company focused exclusively on radiopharmaceuticals. We work with purpose to develop and continually improve best-in-class treatments, and achieve excellence by empowering our team to be trailblazers. In pursuit of providing new options to patients and caregivers all over the globe, POINT Biopharma is committed to accelerating the discovery and development of new products. We are developing complex next-generation radiopharmaceuticals for hard to treat cancers. We are supported by a team of experts, such as our highly experienced global manufacturing team. We are a responsive and agile organization with a proud connection to patients, positioning ourselves to manufacture therapies on-demand for delivery to those in need. 

To learn more about POINT Biopharma Global, visit http://www.pointbiopharma.com/

Company Contact:
Joe McCann, Chief Executive Officer
https://www.linkedin.com/in/joe-mccann-5a9b6bb/
317-543-9957

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.